CorMedix Q1 beats, raises FY2026 guidance as DefenCath utilization ramps

What happened

CorMedix reported Q1 2026 net revenue of $127.4 million, net income of $38.6 million, and adjusted EBITDA of $70.0 million, exceeding the upper end of prior implied quarterly run-rates and prompting an upward revision to full-year 2026 revenue and adjusted EBITDA guidance. The strong start reflects continued DefenCath adoption in dialysis and stable contributions from the Melinta hospital portfolio, with management executing on the front-loaded utilization strategy ahead of the July 1, 2026 TDAPA reimbursement step-down. While the quarter validates the near-term revenue bridge, the second-half pricing reset remains the dominant risk, and the raised guidance still embeds a material sequential decline in H2 2026. Investors should view this as reinforcing the existing thesis rather than eliminating the calendar concentration risk, as the company still faces a net pricing compression in Q3–Q4 2026. The Q1 results reduce the probability of a near-term capital impairment but do not change the medium-term dependency on post-TDAPA contracting outcomes.

Implication

The strong Q1 and raised guidance increase confidence in the front-half revenue plan, reducing near-term downside risk and potentially supporting a re-rating if sustained utilization data emerges. However, the fundamental call still hinges on whether DefenCath can maintain volume and pricing discipline after the July 2026 TDAPA transition. The raised EBITDA guidance provides a larger cushion but does not eliminate the structural step-down. Investors should monitor customer contracting discussions, DefenCath unit KPIs, and the REZZAYO Phase 3 readout (Q2 2026) as the next catalysts. The risk/reward remains favorable for patient holders, but the stock is not yet de-risked beyond H1 2026.

Thesis delta

The Q1 beat and guidance raise improve near-term visibility and reduce the probability of an early bear-case outcome, incrementally supporting the base case. However, the medium-term risk profile is unchanged: the company still must demonstrate that DefenCath utilization momentum can offset the post-TDAPA pricing decline in H2 2026. The thesis shifts from 'can they execute H1' to 'will H1 strength persist into H2 at lower pricing.' No structural thesis break occurs yet; the bull case gains modest support but the bear case remains plausible if pricing concessions accelerate.